First pill for blinding eye disease enters human testing
Disease control
Recruiting now
This is the first study in people for an oral medication called OCT-980, designed to treat a specific genetic form of retinitis pigmentosa, an inherited disease that causes progressive vision loss. The study will first test single doses in healthy volunteers to check safety, then…
Phase: PHASE1, PHASE2 • Sponsor: Octant, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC